Day: January 10, 2023

<div>Magna Announces Date for Q4 & Year End 2022 Results and 2023 Outlook Conference Call</div>

Magna Announces Date for Q4 & Year End 2022 Results and 2023 Outlook Conference Call

AURORA, Ontario, Jan. 10, 2023 (GLOBE NEWSWIRE) — Magna International Inc. (TSX:MG) (NYSE:MGA)  MAGNA ANNOUNCES DATE FOR Q4 & YEAR END 2022 RESULTS and 2023 OUTLOOK CONFERENCE CALL     FRIDAY – FEBRUARY 10, 2023  8:00 AM ET        DIAL IN NUMBERS Toll-Free: 1-800-891-9945 International: 1-416-981-9017 Webcast: www.magna.com Slide presentation will be available on our website prior to the call      REBROADCAST INFORMATION Replay available 2 hours after the call until February 17, 2023 Toll-Free: 1-800-558-5253 International: 1-416-626-4100 Reservation No.: 22025718 INVESTOR CONTACTLouis Tonelli, Vice-President, Investor Relations louis.tonelli@magna.com   905-726-7035 TELECONFERENCE CONTACTNancy Hansford, Executive Assistant, Investor Relations nancy.hansford@magna.com   905-726-7108  

Continue reading

Occidental to Announce Fourth Quarter Results Monday, February 27, 2023; Hold Conference Call Tuesday, February 28, 2023

Occidental to Announce Fourth Quarter Results Monday, February 27, 2023; Hold Conference Call Tuesday, February 28, 2023

HOUSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) — Occidental (NYSE: OXY) will announce its fourth quarter 2022 financial results after close of market on Monday, February 27, 2023, and will hold a conference call to discuss results on Tuesday, February 28, 2023, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at oxy.com/investors. Participants may pre-register for the conference call at https://dpregister.com/sreg/10173524/f531c7c588.         Fourth quarter 2022 financial results will be available through the Investor Relations section of the company’s website. A recording of the webcast will be posted on the website within several hours after the call is completed. About Occidental Occidental is an international energy company...

Continue reading

Optimi Health Announces Re-Appointments to Board of Directors

Optimi Health Announces Re-Appointments to Board of Directors

VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Company’s Annual General Meeting held January 9, 2023. The Company would like to thank departing director Mr. Michael Stier for his service and wishes him well in his future endeavours. Optimi shareholders also re-appointed Smythe LLP as auditor and re-approved the Company’s Equity Incentive Plan. ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances,...

Continue reading

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announced that its research collaborator, Carlos Perez-Stable, PhD, from the University of Miami Miller School of Medicine and Miami Veterans Affairs/Research, today presented new findings from a preclinical study on the Company’s lead drug candidate, rencofilstat, a potent inhibitor of cyclophilins, in a presentation at the 2023 State of Florida Cancer Symposium in Tampa, Florida. The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical...

Continue reading

Dime Community Bancshares to Release Earnings on January 27, 2023

Dime Community Bancshares to Release Earnings on January 27, 2023

HAUPPAUGE, N.Y., Jan. 10, 2023 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company”) today announced that the Company expects to release its earnings for the quarter ended December 31, 2022 before the open of the U.S. equity markets on Friday, January 27, 2023. The Company will conduct a conference call at 8:30 a.m. (ET) on Friday, January 27, 2023, during which Chief Executive Officer (“CEO”), Kevin O’Connor, will discuss the Company’s fourth quarter financial performance. There will be a question-and-answer period after the CEO remarks. The conference call will be simultaneously webcast (listen only) and archived for a period of one year at https://events.q4inc.com/attendee/499210648. Conference Call Details:   Dial-in for Live Call:       United States: 1-844-200-6205 International:   +1-929-526-1599 Access...

Continue reading

Palomar Holdings, Inc. Announces New Fronting Partnership with Advanced AgProtection

Palomar Holdings, Inc. Announces New Fronting Partnership with Advanced AgProtection

~ Palomar Specialty Insurance Company Authorized as the Fourteenth Approved Insurance Provider in the United States by the Federal Crop Insurance Corporation (“FCIC”) ~ ~ Expands PLMR-FRONT into the ~$20 billion United States Crop Insurance Market ~ LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or the “Company”) today announced it has entered into a new multi-year fronting arrangement with Advanced AgProtection, a managing general agent (“MGA”). Advanced AgProtection is a leader in the crop insurance sector based upon their advanced technology and proprietary decisioning tools specific to the United States farming community. Advanced AgProtection provides crop insurance products using their deep expertise and innovative technology and analytics which are designed to manage standard...

Continue reading

K92 Mining Announces Record Annual Production, Achieves Guidance, Record Ore Mined, Ore Processed and Development

K92 Mining Announces Record Annual Production, Achieves Guidance, Record Ore Mined, Ore Processed and Development

Figure 1 Quarterly Total Ore Processed, Development Metres Advanced and Total Mined Material Chart Strong quarterly production, the second highest on record, of 35,538 oz of gold equivalent (“AuEq”)(1) or 31,204 oz gold, 1,827,085 lbs copper and 40,517 oz silver and quarterly sales of 35,212 oz gold, 1,923,116 lbs copper and 44,828 oz silver. Record annual production, increasing 18% year over year, of 122,806 oz AuEq or 107,546 oz gold, 6,247,950 lbs copper and 126,043 oz silver, achieving the guidance range of 115,000 to 140,000 oz AuEq. Record quarterly ore processed of 121,686 tonnes or 1,323 tpd (“tonnes per day”), a 22% increase from Q4 2021. Head grade during the quarter of 8.75 g/t gold, 0.74% copper and 13.31 g/t silver (9.98 g/t AuEq) with metallurgical recoveries for gold of 91.2% and copper of 91.8%. Record daily mill...

Continue reading

Cipher Mining Announces December 2022 Operational Update

Cipher Mining Announces December 2022 Operational Update

Odessa Odessa Data Center Area C Odessa Odessa Data Center Staging Area Produces 225 Bitcoin and Achieves New All-Time High Hash Rate Capacity of 2.8 EH/s in December 2022 NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ:CIFR) (“Cipher” or the “Company”), a leading developer and operator of bitcoin mining data centers, today announced unaudited production and operations updates for December 2022. Key Highlights Key Metrics December 2022* BTC Mined 225 BTC Sold 39 BTC Held 394 Deployed Fleet 28,000 Month End Operating Hash Rate (EH/s) 2.8 *Approximate values Management Commentary In December, in addition to operating its first three data centers, Cipher continued its buildout at Odessa at maximum velocity. Cipher started the month with the potential to mine up to ~3.6 bitcoin in a day at Odessa...

Continue reading

Saratoga Investment Corp. Announces Fiscal Third Quarter 2023 Financial Results

Saratoga Investment Corp. Announces Fiscal Third Quarter 2023 Financial Results

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company (“BDC”), today announced financial results for its 2023 fiscal third quarter, with Net Investment Income (“NII”) per share notably up 30% over the prior quarter and up 84% over the year ago quarter, and Adjusted NII per share up 33% and 45%, respectively, over those same periods. This increase in earnings reflects the positive effects of rising rates on the Company’s asset and credit structure, comprised of income from its largely floating rate assets in contrast to expenses from its largely fixed rate credit liabilities. Summary Financial Information The Company’s summarized financial information is as follows:     For the threemonths ended andas of November 30,2022 For the...

Continue reading

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from 2021.1 Eagle exited 2022 with an approximate 6%2 share of the commercial segment of the pemetrexed market for its PEMFEXY® product, equating to approximately $8 million per quarter in revenue3, and anticipates doubling its share by the end of Q1 2023. The Company bought down future royalties on PEMFEXY profits in exchange for a one-time payment of $15 million.4 Expects U.S. bendamustine franchise decline to be...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.